Lipopolysaccharide (LPS) stimulation of Pancreatic Ductal Adenocarcinoma (PDAC) and macrophages activates the NLRP3 inflammasome that influences the levels of pro-inflammatory cytokines in a co-culture model
This study investigated the effects of LPS-stimulated inflammation on cell proliferation, levels of pro-inflammatory cytokines, and the NLRP3 inflammasome pathway in a co-culture model using PDAC cells and macrophages in the presence or absence of MCC950, a NLRP3-specific inhibitor. The effects of LPS-stimulated inflammation were tested on two PDAC cell lines (Panc 10.05 and SW 1990) co-cultured with RAW 264.7 macrophages. Cell proliferation was determined using the MTT assay. Levels of pro-inflammatory cytokines, IL-1β, and TNF-α were determined by ELISA. Western blot analyses were used to examine the expression of NLRP...
Source: Cancer Biology and Therapy - November 29, 2023 Category: Cancer & Oncology Authors: Hariss G Paremes Sivam Beek Yoke Chin Sook Yee Gan Jia Hao Ng Agnes Gwenhure Elaine Wan Ling Chan Source Type: research
Revealing the inhibitory effect of VASH1 on ovarian cancer from multiple perspectives
Cancer Biol Ther. 2023 Dec 31;24(1):2285817. doi: 10.1080/15384047.2023.2285817. Epub 2023 Nov 27.ABSTRACTThe function of Vasohibin-1 (VASH1) in human cancer has not been thoroughly or comprehensively examined. Here, we identified the tumor suppressor part of VASH1 across cancers, including epithelial ovarian tumors. Our study carefully contrasted the expression of VASH1 in pancancer and nontumorous tissues in a public database to explore its regulatory role in clinical prognosis, diagnosis, tumor purity, and immune cell infiltration. Next, we explored the antitumor mechanism of VASH1 through drug sensitivity, functional e...
Source: Cancer Biology and Therapy - November 27, 2023 Category: Cancer & Oncology Authors: Yan Li Liang Meng Ge Lou Source Type: research
Mathematical modeling predicts pathways to successful implementation of combination TRAIL-producing oncolytic virus and PAC-1 to treat granulosa cell tumors of the ovary
Cancer Biol Ther. 2023 Dec 31;24(1):2283926. doi: 10.1080/15384047.2023.2283926. Epub 2023 Nov 27.ABSTRACTThe development of new cancer therapies requires multiple rounds of validation from in vitro and in vivo experiments before they can be considered for clinical trials. Mathematical models assist in this preclinical phase by combining experimental data with human parameters to provide guidance about potential therapeutic regimens to bring forward into trials. However, granulosa cell tumors of the ovary lack a relevant mouse model, complexifying preclinical drug development for this rare tumor. To bridge this gap, we est...
Source: Cancer Biology and Therapy - November 27, 2023 Category: Cancer & Oncology Authors: Justin Le Sauteur-Robitaille Powel Crosley Mary Hitt Adrianne L Jenner Morgan Craig Source Type: research
Aldolase A promotes cervical cancer cell radioresistance by regulating the glycolysis and DNA damage after irradiation
Cancer Biol Ther. 2023 Dec 31;24(1):2287128. doi: 10.1080/15384047.2023.2287128. Epub 2023 Nov 27.ABSTRACTRadioresistance is the major obstacle that affects the efficacy of radiotherapy which is an important treatment for cervical cancer. By analyzing the databases, we found that aldolase A (ALDOA), which is a key enzyme in metabolic reprogramming, has a higher expression in cervical cancer patients and is associated with poor prognosis. We detected the expression of ALDOA in the constructed cervical cancer radioresistance (RR) cells by repetitive irradiation and found that it was upregulated compared to the control cells....
Source: Cancer Biology and Therapy - November 27, 2023 Category: Cancer & Oncology Authors: Junying Zhou Ningjing Lei Bo Qin Mengyu Chen Shuai Gong Hao Sun Luojie Qiu Fengling Wu Ruixia Guo Qian Ma Yong Li Lei Chang Source Type: research
Revealing the inhibitory effect of VASH1 on ovarian cancer from multiple perspectives
Cancer Biol Ther. 2023 Dec 31;24(1):2285817. doi: 10.1080/15384047.2023.2285817. Epub 2023 Nov 27.ABSTRACTThe function of Vasohibin-1 (VASH1) in human cancer has not been thoroughly or comprehensively examined. Here, we identified the tumor suppressor part of VASH1 across cancers, including epithelial ovarian tumors. Our study carefully contrasted the expression of VASH1 in pancancer and nontumorous tissues in a public database to explore its regulatory role in clinical prognosis, diagnosis, tumor purity, and immune cell infiltration. Next, we explored the antitumor mechanism of VASH1 through drug sensitivity, functional e...
Source: Cancer Biology and Therapy - November 27, 2023 Category: Cancer & Oncology Authors: Yan Li Liang Meng Ge Lou Source Type: research
Mathematical modeling predicts pathways to successful implementation of combination TRAIL-producing oncolytic virus and PAC-1 to treat granulosa cell tumors of the ovary
Cancer Biol Ther. 2023 Dec 31;24(1):2283926. doi: 10.1080/15384047.2023.2283926. Epub 2023 Nov 27.ABSTRACTThe development of new cancer therapies requires multiple rounds of validation from in vitro and in vivo experiments before they can be considered for clinical trials. Mathematical models assist in this preclinical phase by combining experimental data with human parameters to provide guidance about potential therapeutic regimens to bring forward into trials. However, granulosa cell tumors of the ovary lack a relevant mouse model, complexifying preclinical drug development for this rare tumor. To bridge this gap, we est...
Source: Cancer Biology and Therapy - November 27, 2023 Category: Cancer & Oncology Authors: Justin Le Sauteur-Robitaille Powel Crosley Mary Hitt Adrianne L Jenner Morgan Craig Source Type: research
Aldolase A promotes cervical cancer cell radioresistance by regulating the glycolysis and DNA damage after irradiation
Cancer Biol Ther. 2023 Dec 31;24(1):2287128. doi: 10.1080/15384047.2023.2287128. Epub 2023 Nov 27.ABSTRACTRadioresistance is the major obstacle that affects the efficacy of radiotherapy which is an important treatment for cervical cancer. By analyzing the databases, we found that aldolase A (ALDOA), which is a key enzyme in metabolic reprogramming, has a higher expression in cervical cancer patients and is associated with poor prognosis. We detected the expression of ALDOA in the constructed cervical cancer radioresistance (RR) cells by repetitive irradiation and found that it was upregulated compared to the control cells....
Source: Cancer Biology and Therapy - November 27, 2023 Category: Cancer & Oncology Authors: Junying Zhou Ningjing Lei Bo Qin Mengyu Chen Shuai Gong Hao Sun Luojie Qiu Fengling Wu Ruixia Guo Qian Ma Yong Li Lei Chang Source Type: research
miRNA-660-3p inhibits malignancy in glioblastoma via negative regulation of APOC1-TGF β2 signaling pathway
Cancer Biol Ther. 2023 Dec 31;24(1):2281459. doi: 10.1080/15384047.2023.2281459. Epub 2023 Nov 19.ABSTRACTGlioblastoma as the most common and aggressive central nervous system tumor in adults. Its prognosis and therapeutic outcome are poor due to the limited understanding of its molecular mechanism. Apolipoprotein C-1 (APOC1) as a member of the apolipoprotein family that acts as a tumor promoter in various cancers. MicroRNA (miRNA) can silence gene expression and suppress tumor progression. However, the role of APOC1 and its upstream miRNA has not been explored in glioblastoma. Two glioblastoma cell lines (U87 and U251) we...
Source: Cancer Biology and Therapy - November 20, 2023 Category: Cancer & Oncology Authors: Zelin Yang Liang Yang Zhenkai Sun Yuxi Rong Chenglian Bai Qiaoxiang Dong Lin Jian Source Type: research
miRNA-660-3p inhibits malignancy in glioblastoma via negative regulation of APOC1-TGF β2 signaling pathway
Cancer Biol Ther. 2023 Dec 31;24(1):2281459. doi: 10.1080/15384047.2023.2281459. Epub 2023 Nov 19.ABSTRACTGlioblastoma as the most common and aggressive central nervous system tumor in adults. Its prognosis and therapeutic outcome are poor due to the limited understanding of its molecular mechanism. Apolipoprotein C-1 (APOC1) as a member of the apolipoprotein family that acts as a tumor promoter in various cancers. MicroRNA (miRNA) can silence gene expression and suppress tumor progression. However, the role of APOC1 and its upstream miRNA has not been explored in glioblastoma. Two glioblastoma cell lines (U87 and U251) we...
Source: Cancer Biology and Therapy - November 20, 2023 Category: Cancer & Oncology Authors: Zelin Yang Liang Yang Zhenkai Sun Yuxi Rong Chenglian Bai Qiaoxiang Dong Lin Jian Source Type: research
miRNA-660-3p inhibits malignancy in glioblastoma via negative regulation of APOC1-TGF β2 signaling pathway
Cancer Biol Ther. 2023 Dec 31;24(1):2281459. doi: 10.1080/15384047.2023.2281459. Epub 2023 Nov 19.ABSTRACTGlioblastoma as the most common and aggressive central nervous system tumor in adults. Its prognosis and therapeutic outcome are poor due to the limited understanding of its molecular mechanism. Apolipoprotein C-1 (APOC1) as a member of the apolipoprotein family that acts as a tumor promoter in various cancers. MicroRNA (miRNA) can silence gene expression and suppress tumor progression. However, the role of APOC1 and its upstream miRNA has not been explored in glioblastoma. Two glioblastoma cell lines (U87 and U251) we...
Source: Cancer Biology and Therapy - November 20, 2023 Category: Cancer & Oncology Authors: Zelin Yang Liang Yang Zhenkai Sun Yuxi Rong Chenglian Bai Qiaoxiang Dong Lin Jian Source Type: research
miRNA-660-3p inhibits malignancy in glioblastoma via negative regulation of APOC1-TGF β2 signaling pathway
Cancer Biol Ther. 2023 Dec 31;24(1):2281459. doi: 10.1080/15384047.2023.2281459. Epub 2023 Nov 19.ABSTRACTGlioblastoma as the most common and aggressive central nervous system tumor in adults. Its prognosis and therapeutic outcome are poor due to the limited understanding of its molecular mechanism. Apolipoprotein C-1 (APOC1) as a member of the apolipoprotein family that acts as a tumor promoter in various cancers. MicroRNA (miRNA) can silence gene expression and suppress tumor progression. However, the role of APOC1 and its upstream miRNA has not been explored in glioblastoma. Two glioblastoma cell lines (U87 and U251) we...
Source: Cancer Biology and Therapy - November 20, 2023 Category: Cancer & Oncology Authors: Zelin Yang Liang Yang Zhenkai Sun Yuxi Rong Chenglian Bai Qiaoxiang Dong Lin Jian Source Type: research
miRNA-660-3p inhibits malignancy in glioblastoma via negative regulation of APOC1-TGF β2 signaling pathway
Cancer Biol Ther. 2023 Dec 31;24(1):2281459. doi: 10.1080/15384047.2023.2281459. Epub 2023 Nov 19.ABSTRACTGlioblastoma as the most common and aggressive central nervous system tumor in adults. Its prognosis and therapeutic outcome are poor due to the limited understanding of its molecular mechanism. Apolipoprotein C-1 (APOC1) as a member of the apolipoprotein family that acts as a tumor promoter in various cancers. MicroRNA (miRNA) can silence gene expression and suppress tumor progression. However, the role of APOC1 and its upstream miRNA has not been explored in glioblastoma. Two glioblastoma cell lines (U87 and U251) we...
Source: Cancer Biology and Therapy - November 20, 2023 Category: Cancer & Oncology Authors: Zelin Yang Liang Yang Zhenkai Sun Yuxi Rong Chenglian Bai Qiaoxiang Dong Lin Jian Source Type: research
miRNA-660-3p inhibits malignancy in glioblastoma via negative regulation of APOC1-TGF β2 signaling pathway
Cancer Biol Ther. 2023 Dec 31;24(1):2281459. doi: 10.1080/15384047.2023.2281459. Epub 2023 Nov 19.ABSTRACTGlioblastoma as the most common and aggressive central nervous system tumor in adults. Its prognosis and therapeutic outcome are poor due to the limited understanding of its molecular mechanism. Apolipoprotein C-1 (APOC1) as a member of the apolipoprotein family that acts as a tumor promoter in various cancers. MicroRNA (miRNA) can silence gene expression and suppress tumor progression. However, the role of APOC1 and its upstream miRNA has not been explored in glioblastoma. Two glioblastoma cell lines (U87 and U251) we...
Source: Cancer Biology and Therapy - November 20, 2023 Category: Cancer & Oncology Authors: Zelin Yang Liang Yang Zhenkai Sun Yuxi Rong Chenglian Bai Qiaoxiang Dong Lin Jian Source Type: research
hsa_circ_0020378 regulating miR-339-3p/COL1A1 promotes osteosarcoma progression
This study aimed to investigate a novel circRNA, hsa_circ_0020378 (circ_0020378), and elucidate its functions and underlying mechanisms during osteosarcoma progression. The expression levels of circ_0020378, miR-339-3p, and COL1A1 in osteosarcoma cells and tissues were determined using RT-qPCR or Western blotting. CCK8, transwell migration, colony formation, and xenograft experiments were performed to assess the malignancy of osteosarcoma cells. Luciferase and RNA immunoprecipitation (RIP) experiments were employed to validate the interactions of miR-339-3p with circ_0020378 and COL1A1 3'UTR. Osteosarcoma cells and tissues...
Source: Cancer Biology and Therapy - November 18, 2023 Category: Cancer & Oncology Authors: Liang Liu Wenze Huang Source Type: research
hsa_circ_0020378 regulating miR-339-3p/COL1A1 promotes osteosarcoma progression
This study aimed to investigate a novel circRNA, hsa_circ_0020378 (circ_0020378), and elucidate its functions and underlying mechanisms during osteosarcoma progression. The expression levels of circ_0020378, miR-339-3p, and COL1A1 in osteosarcoma cells and tissues were determined using RT-qPCR or Western blotting. CCK8, transwell migration, colony formation, and xenograft experiments were performed to assess the malignancy of osteosarcoma cells. Luciferase and RNA immunoprecipitation (RIP) experiments were employed to validate the interactions of miR-339-3p with circ_0020378 and COL1A1 3'UTR. Osteosarcoma cells and tissues...
Source: Cancer Biology and Therapy - November 18, 2023 Category: Cancer & Oncology Authors: Liang Liu Wenze Huang Source Type: research
